Literature DB >> 32499240

Clinical acceleration of JAK2 p.V617F driven myeloproliferative disease due to a new uncommon homozygous MPL p.Y591D mutation.

Jeremy Ong1,2, Jane I Lin1, Helen Mitchell3, Susan Morgan2, Andrew C Perkins4,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32499240      PMCID： PMC7395288          DOI： 10.3324/haematol.2020.250969

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

Review 1.  Genetic Risk Assessment in Myeloproliferative Neoplasms.

Authors:  Ayalew Tefferi; Alessandro Maria Vannucchi
Journal:  Mayo Clin Proc       Date:  2017-08       Impact factor: 7.616

2.  Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation.

Authors:  Graham W Magor; Michael R Tallack; Nathan M Klose; Debra Taylor; Darren Korbie; Peter Mollee; Matt Trau; Andrew C Perkins
Journal:  J Mol Diagn       Date:  2016-07-19       Impact factor: 5.568

3.  Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia.

Authors:  Fabrice Usseglio; Nathalie Beaufils; Anne Calleja; Sophie Raynaud; Jean Gabert
Journal:  J Mol Diagn       Date:  2016-11-14       Impact factor: 5.568

4.  Targeted deep sequencing in polycythemia vera and essential thrombocythemia.

Authors:  Ayalew Tefferi; Terra L Lasho; Paola Guglielmelli; Christy M Finke; Giada Rotunno; Yoseph Elala; Annalisa Pacilli; Curtis A Hanson; Alessandro Pancrazzi; Rhett P Ketterling; Carmela Mannarelli; Daniela Barraco; Tiziana Fanelli; Animesh Pardanani; Naseema Gangat; Alessandro M Vannucchi
Journal:  Blood Adv       Date:  2016-11-22

5.  Mutations and prognosis in primary myelofibrosis.

Authors:  A M Vannucchi; T L Lasho; P Guglielmelli; F Biamonte; A Pardanani; A Pereira; C Finke; J Score; N Gangat; C Mannarelli; R P Ketterling; G Rotunno; R A Knudson; M C Susini; R R Laborde; A Spolverini; A Pancrazzi; L Pieri; R Manfredini; E Tagliafico; R Zini; A Jones; K Zoi; A Reiter; A Duncombe; D Pietra; E Rumi; F Cervantes; G Barosi; M Cazzola; N C P Cross; A Tefferi
Journal:  Leukemia       Date:  2013-04-26       Impact factor: 11.528

Review 6.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

7.  YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation.

Authors:  Ian S Hitchcock; Maximus M Chen; Jennifer R King; Kenneth Kaushansky
Journal:  Blood       Date:  2008-05-16       Impact factor: 22.113

8.  Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2(V617F) allelic burden.

Authors:  Roberto H Nussenzveig; Ha T Pham; Sherrie L Perkins; Josef T Prchal; Archana M Agarwal; Mohamed E Salama
Journal:  Leuk Lymphoma       Date:  2015-12-23

9.  Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray.

Authors:  Norihiko Kawamata; Seishi Ogawa; Go Yamamoto; Soren Lehmann; Ross L Levine; Yana Pikman; Yasuhito Nannya; Masashi Sanada; Carl W Miller; D Gary Gilliland; H Phillip Koeffler
Journal:  Exp Hematol       Date:  2008-08-23       Impact factor: 3.084

10.  COSMIC: the Catalogue Of Somatic Mutations In Cancer.

Authors:  John G Tate; Sally Bamford; Harry C Jubb; Zbyslaw Sondka; David M Beare; Nidhi Bindal; Harry Boutselakis; Charlotte G Cole; Celestino Creatore; Elisabeth Dawson; Peter Fish; Bhavana Harsha; Charlie Hathaway; Steve C Jupe; Chai Yin Kok; Kate Noble; Laura Ponting; Christopher C Ramshaw; Claire E Rye; Helen E Speedy; Ray Stefancsik; Sam L Thompson; Shicai Wang; Sari Ward; Peter J Campbell; Simon A Forbes
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.